Market Overview

SunTrust Sees Further Pfizer Inc. Bid For AstraZeneca PLC (ADR) 'Highly Likely'

Share:
Related AZN
Benzinga's Daily Biotech Pulse: Novartis Licenses Skin Drug, 2 Stocks To Debut
A Look At Biotech In 2018 And The Biggest Catalysts Coming Up In The Second Half Of The Year
Big Pharma in the red on ramped up pressure on drug prices (Seeking Alpha)
Related PFE
Benzinga Pro's 5 Stocks To Watch Today
Canopy Growth, Delta, GE, Pfizer: 'Fast Money' Picks For July 12
Jane's June Dividend Increases And Income - Retirement Accounts (Seeking Alpha)

Pfizer Inc. (NYSE: PFE) is likely to boost its offer for British drug maker AstraZeneca PLC (ADR) (NYSE: AZN) to $96.28 a share, an analyst said Tuesday.

SunTrust's John Boris said a deal would cut Pfizer's tax rate to 20 percent and said potential Treasury inversion action blocking such action is merely “election year rhetoric.”

The $127 billion offer envisioned by Boris would tack on 6.3 percent to its earlier bid of $120 billion, which AstraZeneca (NYSE: AZN) rejected back in mid-May

AstraZeneca's American Depositary Receipts were recently down two percent at $74.62 from Friday's high, but were still up nearly 26 percent for the year.

Under British rules, AstraZeneca can, starting Tuesday, invite it back for talks or Pfizer can make a single "knock-out" bid which it believes would be accepted. Pfizer (NYSE: PFE) can also start a more conventional bidding process over again, beginning in November.

Posted-In: John Boris SunTrustAnalyst Color News Rumors M&A

 

Related Articles (AZN + PFE)

View Comments and Join the Discussion!